Tarsus [TARS] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Tarsus Pharmaceuticals Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Tarsus Pharmaceuticals Inc. wins in 13 metrics, Axsome Therapeutics Inc. wins in 6 metrics, with 0 ties. Tarsus Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Tarsus Pharmaceuticals Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) -38.69 -50.54 Tarsus Pharmaceuticals Inc.
Price-to-Book Ratio 7.56 105.31 Tarsus Pharmaceuticals Inc.
Debt-to-Equity Ratio 24.18 247.03 Tarsus Pharmaceuticals Inc.
PEG Ratio 0.58 0.79 Tarsus Pharmaceuticals Inc.
EV/EBITDA -32.69 -57.70 Tarsus Pharmaceuticals Inc.
Profit Margin (TTM) -14.72% -28.69% Tarsus Pharmaceuticals Inc.
Operating Margin (TTM) -5.26% -18.38% Tarsus Pharmaceuticals Inc.
Return on Equity -23.39% -252.12% Tarsus Pharmaceuticals Inc.
Return on Assets (TTM) -9.45% -16.81% Tarsus Pharmaceuticals Inc.
Free Cash Flow (TTM) $-22.31M $-93.89M Tarsus Pharmaceuticals Inc.
1-Year Return 38.30% 122.97% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) 5.75 14.64 Tarsus Pharmaceuticals Inc.
Enterprise Value $2.26B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 5.01 14.47 Tarsus Pharmaceuticals Inc.
Gross Profit Margin (TTM) 92.80% 93.71% Axsome Therapeutics Inc.
Revenue per Share (TTM) $11 $13 Axsome Therapeutics Inc.
Earnings per Share (Diluted) $-1.59 $-3.69 Tarsus Pharmaceuticals Inc.
Beta (Stock Volatility) 0.63 0.47 Axsome Therapeutics Inc.
Short % of Float 11.11% 6.56% Axsome Therapeutics Inc.

Tarsus Pharmaceuticals Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

TARS
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Tarsus Pharmaceuticals Inc.2.35%-2.16%-9.00%-23.24%-28.24%-27.25%
Axsome Therapeutics Inc.5.09%-0.45%4.37%42.32%57.95%30.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Tarsus Pharmaceuticals Inc.38.30%248.18%75.32%188.63%188.63%188.63%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Tarsus Pharmaceuticals Inc. vs Axsome Therapeutics Inc.

MetricTARSAXSM
Market Information
Market Cap i$2.62B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i520,263592,425
90 Day Avg. Volume i480,364602,162
Last Close$58.76$233.47
52 Week Range$38.51 - $85.25$96.09 - $238.56
% from 52W High-31.07%-2.13%
All-Time High$84.07 (Dec 24, 2025)$238.56 (May 26, 2026)
% from All-Time High-30.11%-2.13%
Growth Metrics
Quarterly Revenue Growth1.28%0.65%
Quarterly Earnings Growth1.28%0.65%
Financial Health
Profit Margin (TTM) i-0.15%-0.29%
Operating Margin (TTM) i-0.05%-0.18%
Return on Equity (TTM) i-0.23%-2.52%
Debt to Equity (MRQ) i24.18247.03
Cash & Liquidity
Book Value per Share (MRQ)$8.07$1.74
Cash per Share (MRQ)$9.81$6.31
Operating Cash Flow (TTM) i$-12,451,000$-93,405,000
Levered Free Cash Flow (TTM) i$-164,000$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Tarsus Pharmaceuticals Inc. vs Axsome Therapeutics Inc.

MetricTARS (Apr 26, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-38.69-50.54
Forward P/E i21.0429.85
PEG Ratio i0.580.79
Price to Sales (TTM) i5.7514.64
Price to Book (MRQ) i7.56105.31
Market Capitalization
Market Capitalization i$2.62B$9.51B
Enterprise Value i$2.26B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i5.0114.47
Enterprise to EBITDA i-32.69-57.70
Risk & Other Metrics
Beta i0.630.47
Book Value per Share (MRQ) i$8.07$1.74

Financial Statements Comparison: Tarsus Pharmaceuticals Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTARS (2025)AXSM (2025)
Revenue/Sales i451.36M638.50M
Cost of Goods Sold i30.68M47.48M
COGS % of Revenue i6.8%7.4%
Gross Profit i420.68M591.02M
Gross Margin i93.2%92.6%
Research & Development i64.32M183.28M
Operating Income (EBIT) i-70.97M-169.24M
Operating Margin i-15.7%-26.5%
EBITDA i-54.20M-160.17M
EBITDA Margin i-12.0%-25.1%
Pre-Tax Income i-64.36M-183.70M
Pre-Tax Income % of Revenue i-14.3%-28.8%
Income Tax i2.06M-530,000
Income Tax % of Revenue i0.5%-0.1%
Net Income (Profit) i-66.42M-183.17M
Profit Margin i-14.7%-28.7%

Balance Sheet & Liquidity Metrics

MetricTARS (2025)AXSM (2025)
Cash & Equivalents i183.64M322.93M
Total Current Assets i522.78M588.99M
Total Current Assets % of Revenue i115.8%92.2%
Total Current Liabilities i135.70M378.84M
Total Current Liabilities % of Revenue i30.1%59.3%
Long-Term Debt i72.44M145.13M
Long-Term Debt % of Revenue i16.0%22.7%
Total Shareholders Equity i343.43M88.30M
Retained Earnings i-426.63M-1.31B
Retained Earnings % of Revenue i-94.5%-204.5%
Property, Plant & Equipment i11.65M562,000

Cash Flow Statement Comparison

MetricTARS (2025)AXSM (2025)
Operating Cash Flow i-10.64M-185.86M
Operating Cash Flow % of Revenue i-2.4%-29.1%
Capital Expenditures i-9.86M-480,000
Free Cash Flow i-22.31M-93.89M
FCF Margin i-4.9%-14.7%
Debt Repayment iN/A-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTARSAXSM
Shares Short i4.58M2.83M
Short Ratio i8.984.92
Short % of Float i11.11%6.56%
Shares Outstanding i42.55M50.88M
Float Shares i32.26M43.24M
% Held by Insiders i3.14%15.47%
% Held by Institutions i108.06%76.52%
% Held by Public i-11.20%8.01%

Dividend Analysis & Yield Comparison: Tarsus Pharmaceuticals Inc. vs Axsome Therapeutics Inc.

MetricTARSAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A